Ligand id: 8997

Name: ligelizumab

No information available.
Summary of Clinical Use
Several Phase II clinical trials are underway to evaluate the potential of QGE031 as a treatment for asthma and chronic spontaneous urticaria [2].
Mechanism Of Action and Pharmacodynamic Effects
IgE acts as an environmental sensor facilitating an immune response via the high-affinity IgE receptor, FcεRI. This action sensitizes mast cells to specific antigens which, upon allergen exposure, release pro-inflammatory cytokines and other mediators of the allergic response. Ligelizumab is designed to bind to circulating IgE, thereby reducing IgE-mediated responses.